Capital Vii Fcpr Sofinnova Net Worth

The estimated Net Worth of Capital Vii Fcpr Sofinnova is at least $742 Million dollars as of 20 August 2020. Capital Sofinnova owns over 55,358 units of Shockwave Medical stock worth over $649,029,368 and over the last 6 years Capital sold SWAV stock worth over $93,245,149.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Capital Sofinnova SWAV stock SEC Form 4 insiders trading

Capital has made over 12 trades of the Shockwave Medical stock since 2019, according to the Form 4 filled with the SEC. Most recently Capital sold 55,358 units of SWAV stock worth $3,322,034 on 20 August 2020.

The largest trade Capital's ever made was selling 650,000 units of Shockwave Medical stock on 4 September 2019 worth over $22,327,500. On average, Capital trades about 161,951 units every 27 days since 2019. As of 20 August 2020 Capital still owns at least 1,938,848 units of Shockwave Medical stock.

You can see the complete history of Capital Sofinnova stock trades at the bottom of the page.

What's Capital Sofinnova's mailing address?

Capital's mailing address filed with the SEC is C/O SHOCKWAVE MEDICAL, INC., 5403 BETSY ROSS DRIVE, SANTA CLARA, CA, 95054.

Insiders trading at Shockwave Medical

Over the last 6 years, insiders at Shockwave Medical have traded over $488,603,927 worth of Shockwave Medical stock and bought 30,000 units worth $510,000 . The most active insiders traders include James E Deerfield Mgmt L.P...., Antoine Papiernik, and Capital Vii Fcpr Sofinnova. On average, Shockwave Medical executives and independent directors trade stock every 8 days with the average trade being worth of $10,693,924. The most recent stock trade was executed by Trinh Phung on 17 May 2024, trading 19,763 units of SWAV stock currently worth $121,740.

What does Shockwave Medical do?

shockwave medical is revolutionizing the interventional treatment of advanced cardiovascular disease by developing technology that targets calcified plaque. inspired by 30-years of safety and efficacy in kidney stone treatment, our lithoplasty® family of catheters delivers localized lithotripsy at the site of cardiovascular calcium that enables gentle balloon dilatation of calcified, stenotic arteries. lithoplasty devices use sonic pressure waves to preferentially impact hard tissue, disrupting calcium, while leaving soft tissue undisturbed. an integrated balloon catheter then dilates the calcified lesion at low-pressure, restoring blood flow. in peripheral vascular clinical study of moderate and severely calcified lesions in 95 patients, lithoplasty technology demonstrated safety and consistent procedure success with low procedural complications. the technology is inherently familiar, easy to use, operates with just the push of a button, and works with existing cardiovascular treatmen

Complete history of Capital Sofinnova stock trades at Shockwave Medical

Shockwave Medical executives and stock owners

Shockwave Medical executives and other stock owners filed with the SEC include:

• Douglas Godshall,
  President, Chief Executive Officer, Director
• Daniel Puckett,
  Chief Financial Officer
• Douglas E. Godshall,
  Pres, CEO & Director
• Isaac Zacharias,
  Chief commercial Officer
• Isaac Zacharias,
  Chief Commercial Officer
• Daniel Puckett MBA,
  CFO, Principal Financial Officer & Sec.
• Colin Cahill,
  Independent Director
• F. Thomas Watkins,
  Independent Director
• Antoine Papiernik,
  Independent Director
• Frederic Moll,
  Independent Director
• C. Raymond Larkin,
  Independent Chairman of the board
• Laura Francis,
  Independent Director
• Maria Sainz,
  Director
• Trinh Phung,
  Chief Accounting Officer, Principal Accounting Officer & VP of Fin.
• Robert Fletcher,
  VP of Marketing
• Rob Williamson Jr.,
  VP of Sales
• Hajime Tada J.D.,
  Gen. Counsel & Sec.
• Debbie Kaster,
  Head of Investor Relations
• Mike Maszy,
  VP of Operations
• John M. Adams,
  Co-Founder and Technical Advisor
• Daniel Hawkins,
  Founder and Sr. Advisor
• Sara Toyloy,
  Director
• Capital Vii Fcpr Sofinnova,
  10% owner
• James E Deerfield Mgmt L.P....,
  
• Dan Puckett,
  Chief Financial Officer
• Associates Vii, L.P.Venrock...,
  
• Trinh Phung,
  SVP, Finance
• Kevin J. Ballinger,
  Director
• Renee Gaeta,
  Chief Financial Officer